ilrun Antibody

What is ILRUN and why is it significant for antibody-based research?

ILRUN (inflammation and lipid regulator with UBA-like and NBR1-like domains) is a highly conserved protein found in nearly all metazoans that was initially identified as a proviral factor for Hendra virus infection but has since been characterized as an inhibitor of the transcription regulators p300 and CREB-binding protein (CBP) . ILRUN has recently gained significance due to its newly discovered role as a regulator of the renin-angiotensin-aldosterone system (RAAS) and as an antiviral factor against SARS-CoV-2 .

Antibody-based detection of ILRUN is particularly valuable because it regulates multiple cellular pathways with implications for infectious disease, cancer, obesity, and cardiovascular disease research . ILRUN's ability to downregulate ACE2 (the SARS-CoV-2 receptor) expression and inhibit viral replication makes it a promising target for therapeutic development, necessitating reliable antibody detection methods .

What are the key structural domains of ILRUN that antibodies should target?

ILRUN contains several distinct domains that may serve as antibody targets, with the N-terminal ubiquitin-associated (UBA)-like and central neighbour of BRCA1 gene 1 (NBR1)-like domains being evolutionarily well-conserved in animals . Both these domains contribute to ILRUN-mediated inhibition of IRF3 signaling, while the C-terminal disordered region appears dispensable for this function .

When selecting antibodies for ILRUN detection, researchers should consider:

• Antibodies targeting the UBA-like domain for studying ubiquitin-related interactions

• Antibodies targeting the NBR1-like domain, whose crystal structure has been determined

• Antibodies recognizing full-length ILRUN for general expression studies

• Domain-specific antibodies to distinguish functional regions in mechanistic studies

What techniques can validate ILRUN antibody specificity in experimental systems?

A methodological approach to validating ILRUN antibody specificity should include:

• Genetic validation: Testing antibodies in ILRUN knockdown cells using siRNA (as demonstrated in SARS-CoV-2 studies) to confirm signal reduction

• Overexpression controls: Comparing antibody signal in cells with endogenous versus overexpressed ILRUN

• Western blot analysis: Confirming a single band of appropriate molecular weight

• Immunoprecipitation followed by mass spectrometry: Verifying ILRUN is the predominant protein detected

• Cross-reactivity testing: Especially important given ILRUN's evolutionary conservation across species

What tissue expression patterns should be considered when using ILRUN antibodies?

Based on transcript expression data mining, ILRUN appears most abundant in testis and activated B-cells . This expression pattern should inform experimental design when using ILRUN antibodies. Researchers should consider:

• Higher baseline expression expected in reproductive tissues and immune cells

• Expression levels may vary significantly between tissue types

• Normalizing antibody signals to known expression patterns

• Performing appropriate positive controls with tissues known to express ILRUN

How can antibodies help elucidate ILRUN's regulation of the RAAS pathway?

ILRUN has been identified as a novel regulator of the renin-angiotensin-aldosterone system, with significant implications for SARS-CoV-2 infection and various disease states . A methodological approach using antibodies would include:

• Co-immunoprecipitation studies: Using ILRUN antibodies to pull down associated RAAS components and identify direct protein interactions

• ChIP-seq analysis: Employing ILRUN antibodies to identify genomic binding sites near RAAS gene promoters

• Immunofluorescence co-localization: Determining spatial relationships between ILRUN and ACE2 in various cell types

• Proximity ligation assays: Detecting close associations between ILRUN and p300/CBP at RAAS gene regulatory elements

These approaches can help determine whether ILRUN regulates RAAS components directly or indirectly through its effects on p300/CBP, as the ACE2 promoter region contains a p300/CBP binding site .

What methodological considerations are important when using ILRUN antibodies in viral infection studies?

Research has demonstrated that ILRUN functions as an antiviral factor for SARS-CoV-2, likely through regulating expression of viral entry receptors including ACE2, TMPRSS2, and CTSL . When designing experiments using ILRUN antibodies in this context, researchers should consider:

• Temporal dynamics: Monitor ILRUN expression before and during infection using time-course immunoblotting

• Subcellular localization changes: Track ILRUN redistribution during infection using fractionation and immunofluorescence

• Viral protein interactions: Investigate potential direct interactions between ILRUN and viral components using co-immunoprecipitation

• Cell-type specificity: Compare ILRUN expression in susceptible versus resistant cell types

Additionally, researchers should be aware that ILRUN may exhibit different functions depending on the virus; it was initially identified as proviral for Hendra virus but is antiviral for SARS-CoV-2 .

How can antibodies be used to investigate ILRUN's interaction with the ISG15 pathway?

ILRUN promotes basal transcription of ISG15, a host member of the ubiquitin family targeted by SARS-CoV-2 as an immune evasion mechanism . Given ILRUN contains a UBA-like domain that generally facilitates binding to ubiquitin and ubiquitin-like proteins, it may directly interact with ISG15 . Methodological approaches include:

• Co-immunoprecipitation with anti-ILRUN antibodies: To detect ISG15 interactions

• Proximity labeling techniques: Using ILRUN antibodies with conjugated enzymes to identify nearby proteins

• ISGylation assays: Determining if ILRUN itself is ISGylated using antibodies against both proteins

• Domain-specific antibodies: Targeting the UBA-like domain to block potential ISG15 interactions

These approaches could help elucidate whether ILRUN directly binds ISG15 or regulates its function through other mechanisms.

What are the optimal conditions for using ILRUN antibodies in different applications?

Based on experimental approaches used in ILRUN research, the following conditions should be considered:

Researchers should note that optimization may be required based on the specific antibody and experimental system, as standardized protocols specifically for ILRUN antibodies are still emerging .

How should researchers approach contradictory findings when using ILRUN antibodies?

When faced with conflicting results in ILRUN research using antibodies, consider:

• Domain-specific functions: ILRUN may exhibit different activities through its distinct domains; using domain-specific antibodies may resolve apparent contradictions

• Cell type differences: ILRUN expression varies significantly between tissues; ensure proper controls for each system

• Context-dependent roles: ILRUN functions differently in various viral infections (proviral for Hendra virus but antiviral for SARS-CoV-2)

• Technical validation: Confirm antibody specificity using genetic approaches (siRNA knockdown) as performed in published ILRUN studies

• Post-translational modifications: Different antibodies may recognize modified versus unmodified forms of ILRUN

A systematic approach using multiple antibodies and validation techniques can help resolve contradictory findings.

How can ILRUN antibodies be used to study its role in disease conditions beyond viral infection?

ILRUN has been associated with increased risk of obesity, coronary artery disease, and altered timing of pubescent growth spurts through SNP associations . Antibody-based methodologies for these conditions include:

• Immunohistochemistry: Compare ILRUN expression in healthy versus diseased tissues (especially cardiovascular samples) using standardized scoring methods

• Co-immunoprecipitation: Identify tissue-specific protein interaction networks in different disease states

• Phosphorylation-specific antibodies: Detect potential post-translational modifications that may differ in disease states

• Proximity ligation assays: Investigate ILRUN's interactions with RAAS components in adipose tissue from obese patients

These approaches can help determine whether ILRUN's association with these conditions is through its regulation of RAAS components, which are known to be upregulated in adipocytes as a result of obesity .

What emerging antibody-based technologies might advance ILRUN research?

Several innovative approaches could enhance ILRUN investigation:

• Nanobodies and single-domain antibodies: Smaller antibody fragments may access ILRUN epitopes with less steric hindrance

• Antibody-based proximity labeling: Techniques like BioID or APEX2 fused to anti-ILRUN antibodies could map the local interactome

• Intrabodies: Genetically encoded antibody fragments targeting ILRUN in living cells to monitor dynamics

• Domain-specific degradation: Using antibody-based degrader technologies to selectively target specific ILRUN domains

• Multiplexed imaging: Simultaneous detection of ILRUN with RAAS components and viral proteins in tissue sections

These technologies could help resolve the complex roles of ILRUN in different cellular contexts.

How might antibody studies help develop ILRUN-targeted therapeutics for SARS-CoV-2?

Given ILRUN's newly discovered role as an antiviral factor that downregulates ACE2, TMPRSS2, and CTSL expression, antibody studies could facilitate therapeutic development through:

• Epitope mapping: Identifying functionally important regions of ILRUN that could be targeted by small molecules

• Conformational antibodies: Detecting active versus inactive ILRUN states to guide drug design

• Activity assays: Developing antibody-based assays to screen for compounds that enhance ILRUN's ability to downregulate ACE2

• Biomarker development: Using anti-ILRUN antibodies to assess expression levels as potential predictors of COVID-19 susceptibility

These approaches could contribute to novel antiviral strategies targeting host factors critical to SARS-CoV-2 infection, potentially leading to broader antiviral applications beyond SARS-CoV-2.